2026年9月9日，石药集团有限公司（01093）发布自愿公告称，其自主研发的促性腺激素释放激素（GnRH）受体激动剂——戈舍瑞林缓释注射液（SYH 9102注射液）已获国家药品监督管理局批准在中国开展临床试验。 据公告，SYH 9102为全球首款获批开展临床试验的即用型戈舍瑞林缓释注射液。产品采用石药集团长效递送技术平台，通过皮下注射后形成原位药物贮库，实现每月给药一次的长效释放。 与已上市的戈舍瑞林长效制剂相比，该产品使用更细针头、无需专用植入针或复杂配制操作，且注射体积更小，旨在降低注射部位损伤与疼痛感，从而提升患者用药便捷性和依从性。 临床前研究结果显示，SYH 9102在血浆睾酮抑制、睾酮去势率及去势状态维持时长方面均优于市售微球制剂，且具备良好安全性。 此次获批的临床适应症为治疗实体瘤患者。公告同时指出，SYH 9102亦可应用于子宫内膜异位症等雌激素依赖性疾病领域，具备进一步开发潜力。石药集团表示，该项目的推进为公司长效制剂技术平台及产品管线扩展奠定了基础。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.